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Abstract
Purpose of Review Advances in genomic medicine have the potential to revolutionise cancer patient care by driving forwards the
clinical practice of precision oncology. This review aims to outline how genomic medicine advances may alter the care of cancer
patients and their families over the next 10 years.
Recent Findings The translation of oncogenomic advances into the clinical environment will likely be facilitated by the increas-
ing availability of next-generation sequencing technologies and the increasing genomic literacy of healthcare professionals. The
implementation of the centralised, nationwide NHS GenomicMedicine Service promises to improve equity of cancer care and to
facilitate personalisation of almost every stage of the care pathway, from informing population screening and how we diagnose
cancer to delivering prognoses and surveillance. Advances in cancer pharmacogenomics, and other “omics” technologies, have a
tremendous potential to optimise patient care. Genomic medicine advances will also enhance the care offered to cancer patients’
families.
Summary Genomic medicine advances are likely to transform almost every aspect of a cancer patient’s care pathway. Cancer
care will profoundly improve over the next decade, increasing UK cancer survival rates and improving patient outcomes.
Keywords Cancer genomics . Oncogenomics . Cancer care pathway . Future of medicine . Cancer treatment . NHS . Genomic
Medicine Service
Introduction
Less than a generation ago, a cancer diagnosis was a “death
sentence”. Over the last decade, the incidence of cancer in the
UK has increased by 5% [1]. However, the prognosis for the
field of cancer care, and for those patients and their families
who will depend upon it a decade from now, is bright.
Advances in genomic medicine will drive forwards the clini-
cal practice of precision oncology and have the potential to
revolutionise and personalise almost every aspect of cancer
care (Figure 1).
Driving Factors
The translation of oncogenomic advances into the clinical
environment will likely be driven by two key factors: the
increased availability of next-generation sequencing (NGS)
technologies and the enhanced genomic literacy of healthcare
professionals.
Increased Availability of Next-Generation Sequencing
Technologies
With the advent of NGS technologies just over 10 years ago,
the cost of whole genome sequencing (WGS) has rapidly re-
duced [2], facilitating its widespread availability and conse-
quent application to basic and clinical cancer research and
cancer patient care. The increased affordability of WGS en-
abled Genomics England, in partnership with NHS England,
to deliver the 100,000 Genomes Project which sequenced both
the germline and tumour genomes of over 15,000 cancer pa-
tients in the UK [3] and returned clinically actionable findings
for many participants and their families. Moreover, the
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100,000 Genomes Project now constitutes an invaluable glob-
al research resource, enabling the return of clinically action-
able results for more participants as well as future patients and
their families. Following its completion, NHS England
established the NHS Genomic Medicine Service to deliver
genetic testing to patients with rare disease and cancer, pro-
viding a direct pathway for advances in oncogenomics to
reach future patients.
Enhanced Genomic Literacy of Healthcare
Professionals
In their 2020 “Strategic vision for improving human health at
The Forefront of Genomics”, the National Human Genome
Research Institute stated that “to fully realize the benefits of
genomic advances” [4•], it is essential to enhance genomic
literacy among healthcare professionals. In the UK in 2019,
the recommendations of The Topol Review supported the
aims of the NHS Long Term Plan, which includes the
upskilling of the NHS workforce to promote the translation
of genomic advances into the clinical environment [5]. Over
the last decade, several educational initiatives have been
launched to enhance the genomic literacy of the existing and
future NHS workforce: Health Education England established
the Genomics Education Programme to deliver “genomics
education, training and experience for the healthcare work-
force” [6]; and the General Medical Council stipulated in their
Outcomes for Graduates that “newly qualified doctors must be
able to apply... knowledge relating to... genetics, genomics
and personalised medicine” to medical practice and integrate
this into patient care [7].
Equity of Care
Throughout the past decade, the effect of the “inexcusable”
(Macmillan [8]) and “unacceptable” (Cancer Research UK
[8]) postcode lottery on cancer patient survival has
scandalised the media and general public with, according to
Juliet Bouverie, Director of Services and Influencing at
Macmillan Cancer Support, “6,000 people dying needlessly
within 12 months of being diagnosed with cancer every year”
[9]. However, the NHSGenomicMedicine Service, a network
of local Genomic Laboratory Hubs underpinned by a single
National Genomic Testing directory, will centralise
oncogenomic services. Consistent and equitable oncogenomic
care is in our sights, and, given that oncogenomics will influ-
ence almost every aspect of patient care, we can surely hope
that within 10 years’ time, all patients diagnosed with the
same cancer will receive comparable care, irrespective of
postcode.
Population Screening
In 2014, nearly half of all cancers were diagnosed at a late
stage [10] and hence associated with poorer prognoses and
patient outcomes. Advances in population screening promise
to improve these aspects of cancer care.
Genetic Screening
Our understanding of the genetic architecture of cancer sus-
ceptibility has greatly expanded over the last few decades. The
high prevalence and mortality rate of some cancers, coupled
with the availability of effective preventive interventions, sig-
nify that the time is upon us to utilise genomic risk factors to
personalise national cancer screening and prevention
programmes and to stratify the population to optimise early
detection.
One approach will be to identify carriers of high-risk var-
iants in cancer susceptibility genes, such as BRCA1, BRCA2,
MLH1 andMSH2 [11•]. Currently in the UK, fewer than 10%
of pathogenic BRCA variant carriers have been identified [12],
despite the progressively lower threshold for testing based on
family history and the expansion of cascade screening.
Population risk profiling for breast, ovarian and colorectal
cancers would be highly clinically valuable: frequency-
penetrance profiles of pathogenic variants in BRCA1,
BRCA2,MLH1 andMSH2 with breast, ovarian and colorectal
cancers, respectively, are strong [13, 14]; breast and colorectal
cancers are common and account for a large proportion of
cancer deaths in the UK [1, 15]; and effective risk-reducing
measures, such as screening, chemoprevention and surgery,
are widely available for all three cancers [16, 17].
Furthermore, there is increasing evidence demonstrating that
population screening for pathogenic variants in BRCA1,
BRCA2, MLH1 and MSH2 would be highly cost-effective
[18]. Since both clinical and health-economic evidence impli-
cate population-wide testing to identify carriers of pathogenic
variants in these genes, the implementation of such a pro-
gramme is anticipated.
A vast number of polymorphisms that influence cancer risk
have been identified through genome-wide association studies
(GWAS) and can be combined into polygenic risk scores
(PRS). The potential clinical utility of PRS-informed screen-
ing for many different cancers has been well-described [19,
20]: incorporating PRS with conventional risk factors im-
proves overall risk predictions and stratification [21•]; and
Fig. 1 The future of precision oncology. A flowchart depicting the stages
of a cancer care pathway: red boxes represent stages that will likely be
personalised due to the clinical application of advances in genomic
medicine within the the next 10 years; blue boxes represent the other
stages
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high polygenic risk explains 4.0–30.3% of cases, often ex-
ceeding the estimated contributions of modifiable risk factors
and family history [21]. Integrating PRS with other clinical
risk factors can personalise risk calculations and modify
screening recommendations. For example, NICE currently
recommends triennial mammograms for most women over
50 years of age [22]; however, a multi-factor risk-based
model that includes PRS would identify 16.1% of women
with a greater 10-year risk of breast cancer than the aver-
age 50-year-old, implicating earlier screening [23•].
Conversely, 32.0% of women would be identified as hav-
ing a lower breast cancer risk at age 50, and delayed
screening, to reduce the risk of harm from false positive,
could be considered [23]. Trials investigating the benefit
of integrating PRS to determine screening eligibility are
currently ongoing [24], and their results may implicate
population-wide PRS calculations to personalise the na-
tional breast cancer screening programme.
However, PRS calculated from the results of GWAS with
participants from one ancestral group cannot be reliably trans-
ferred to populations of different ancestries [25]. Given that
the majority of GWAS has been performed using participants
of European ancestry, inequitable access to PRS-informed
aspects of healthcare is of major concern. With the increasing
discussions surrounding systemic racism and decolonising
healthcare, it is hoped that these efforts will be reflected in
future genomics studies so that powerful tools, such as PRS,
can be made clinically available to all members of our diverse
population.
Over the next 10 years, several key advances will likely
encourage the clinical application of PRS to population
screening for many different cancer types. Not only will more
GWAS be performed to investigate the polygenic component
of more cancers, but an increasing number will employWGS,
thereby eliminating the imputation stage and enabling detec-
tion of rarer variants that may influence cancer risk.
Furthermore, GWAS will recruit larger numbers of partici-
pants, increasing the power of polymorphism-cancer associa-
tions. These advances will improve the accuracy and hence
the potential clinical utility of PRS. In addition, the extremely
low cost of microarrays would facilitate the implementation of
population-wide genotyping to determine individuals’ PRS
for different cancers.
Asymptomatic Screening
Promising progress has been made in developing liquid biop-
sies that detect tumour-specific genomic biomarkers, such as
circulating tumour DNA (ctDNA). The sensitivity of technol-
ogies to detect ctDNA in asymptomatic patients with early-
stage tumours, which typically release lower levels of ctDNA,
has hindered their clinical application as population screening
tools. There are many unanswered questions pertaining to the
utility of a ctDNA screening tool, such as whether it can detect
a sufficient number of cancers at a treatable stage.
Later this year, a pilot study of the Galleri blood test—an
innovative blood test, developed by GRAIL, that can detect
the early stages of more than 50 types of cancer—will be
launched [26]. In this study, 140,000 asymptomatic partici-
pants aged 50–79 years will receive annual blood tests for 3
years [26]. The results, which are expected by 2023, could
implicate the rolling out of this service to more individuals
throughout the UK or the selection of high-risk cohorts. It is
hoped that this test will help achieve the goals set in the NHS
Long Term Plan for earlier diagnosis of most cancers by 2028
[26, 27].
Diagnosing Cancer
How we diagnose cancer will likely change over the next
decade—both in terms of the diagnostic tests performed and
the classification of the diagnoses reached.
Diagnostic Tests
In addition to their potential use as a population screening
tool, liquid biopsies may be utilised as a diagnostic tool.
A liquid biopsy requires a simple blood test. For some
patients presenting with late-stage disease, who are too unwell
to tolerate a general anaesthetic and undergo tissue biopsy
procedures, a liquid biopsy would facilitate a cancer diagnosis
and the commencement of appropriate therapies.
Additionally, since blood tests are easily accessible, liquid
biopsies may be requested by primary care physicians when
patients initially clinically present with suspicious symptoms,
speeding up the time taken to reach a diagnosis. Several up-
coming studies will assess the potential clinical utility of liq-
uid biopsies to detect ctDNA in symptomatic patients where a
cancer diagnosis is suspected. In the GRAIL pilot study
25,000 people with possible cancer symptoms will be offered
the Galleri test [26]. The PREVAIL-ctDNA pilot study will
aim to detect ctDNA in patients presenting with suspected
pancreatic, lung, bladder and colorectal cancers and gastroin-
testinal stromal tumours [28] and to demonstrate that replac-
ing tissue biopsies with liquid biopsies can enable clinicians to
stratify patients and personalise cancer treatment earlier in the
care pathway.
In tertiary care, genomic biomarkers may inform diagnoses
for more complex cases. Proof-of-concept studies have dem-
onstrated the potential clinical utility of microRNAs to detect
germ-cell tumours—microRNA levels detected in the cere-
brospinal fluid of two patients with abnormal pituitary stalk
thicknesses that were too small to biopsy, accurately discerned
which patient had a malignant germ-cell tumour and which
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did not [29]. Further studies with larger sample sizes may
implicate microRNA testing in some patients.
The outcomes of the GRAIL and PREVAIL pilot studies,
and future trials, may demonstrate the clinical utility of liquid
biopsies for detecting tumour-specific biomarkers, enhancing
our future diagnostic abilities and becoming part of routine
clinical practice, from primary to tertiary care.
Cancer Classification
I predict that over the next decade a new system of cancer
classification, primarily based on tumour mutational profile
rather than histological findings, will be developed, providing
more clinically relevant information for the practice of preci-
sion oncology. For example, the same mutational signatures
that arise from passenger mutations during oncogenesis are
present in a broad range of cancer types—signature 2 has been
found in 22 cancer types and attributed to the activity of the
AID/APOBEC family of cytidine deaminases [30•]—and
could enable cancer diagnoses that reflect the aetiology in a
tumour-agnostic manner. Incorporating the mutational profile
of tumours into cancer diagnoses in this way, or identifying
driver mutations, will enable earlier access to targeted
therapies.
Pharmacogenomics and Targeted Therapies
Over the past two decades, major advances in cancer
pharmacogenomics have transformed patient care. The next
decade will likely see further advances in pharmacogenomics,
as well as in other “omics” technologies, which will translate
into clinical practice and improve cancer patient care.
Gold Standard Model of Personalised Oncology
WGS of the somatic and germline genomes of cancer patients
enables clinicians to tailor treatment to the mutational profile
of the tumour and deliver personalised medicine: identifying
clinically actionable driver mutations, such as in BRCA-muta-
tion positive ovarian cancer, may implicate certain existing
targeted therapies, namely the PARP inhibitor Olaparib [31];
and identifying a high tumour mutation burden may implicate
immunotherapy, for example, hypermutated breast cancers
may be more susceptible to PD-1 inhibitors [32].
However, while the NHS Genomic Medicine Service can
provide the infrastructure to deliver these genetic tests, a gold
standard model of how to integrate genetic testing results into
clinical care pathways is needed. The Personalised Breast
Cancer Programme (PBCP) may provide this. The pilot study
of the PBCP, in 2016, was the first time that NHS breast
cancer patients were offered WGS as part of routine treatment
[33]. The aim of the study was to not only advance research
but also to directly benefit the patients who donated samples
and were undergoing treatment—often genetic analysis of tu-
mours takes too long to benefit the patients who donate sam-
ples. The PBCP demonstrated that it is possible to return ge-
netic testing results within 12 weeks of sampling—on aver-
age, turnaround time was 6–9 weeks—thereby enabling clini-
cians to react and alter treatment to optimise patient care [34].
The success of the PBCP has facilitated the rolling out of this
service to more breast cancer patients in other centres across
the UK [34]. The PBCP promises a model of gold-standard
personalised oncology and a template that can be adapted to
other cancer types. Within the next 10 years, the turnaround
time of genetic testing results will likely decrease, and wemay
even see some first-line therapies prescribed that are informed
by the mutational profile of patients’ tumours.
Clinical Trial Enrolment
Some driver mutations identified in patients are currently not
clinically actionable with respect to licenced therapies. They
could, however, still have implications in clinical manage-
ment and in the research and clinical trial setting. The
centralised NHS Genomic Medicine Service will enable
swifter enrolment to nationwide clinical trials that will stratify
patients based on the driver mutations present in their tu-
mours. This may improve the outcomes for participating pa-
tients. Furthermore, the larger sample sizes of current and
future nationwide trials will improve the statistical power of
results, providing more robust clinical evidence for
personalised medicine in oncology. This will support the clin-
ical approval of these drugs, leading to greater availability and
numbers of driver-mutation-targeting drugs within the next
decade.
Mutational Signatures
Driver mutations cannot be identified in all tumours.
Mutational signatures may inform therapeutic decisions in
10 years’ time, thus harnessing the full power of WGS.
Although not yet clinically validated, some mutational signa-
tures show pharmacogenomic promise—signatures 6, 15, 20
and 26 are associated with defective DNA mismatch repair
[30•], and therefore tumours with these signatures may be
susceptible to checkpoint inhibitors. The same mutational sig-
natures are present in a broad range of cancer types, and there-
fore their potential therapeutic yield is high.
Immunotherapy
In 2013 , cance r immunothe rapy was Sc ience ’ s
“Breakthrough of the Year” [35]. One of the outstanding
scientific achievements within this field was the develop-
ment of chimeric antigen receptor (CAR) T-cell therapy.
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CAR T-cell therapy involves harvesting a patient’s T-cells,
genetically editing them to recognise and attack cancer cells,
expanding the population of the genetically edited T-cells and
reintroducing them into the patient. Challenges to the clinical
implementation of this therapy include mitigation of toxicity
and quality control of genetically engineered T-cells.
However, towards the end of the last decade, the NHS began
to offer this revolutionary therapy to children and adults with
certain haematological malignancies, such as specific sub-
types of non-Hodgkin lymphoma [36]. At the start of this year,
this was expanded to include certain patients with mantle cell
lymphoma [37]. Over the next 10 years, this personalised
medicine will likely continue to be offered to more patients
with a broader range of cancers.
In recent years, blockade of the programmed death 1 (PD-
1) pathway has emerged as a highly effective therapy for tu-
mours with a high mutational burden. The PD-1 pathway is
upregulated in many tumours, microenvironments and im-
mune cells and, via negative feedback mechanisms, inacti-
vates T-lymphocytes and contributes to blocking the “cancer
immunity cycle” [38]. PD-1 pathway blockades have evoked
a remarkable clinical response in patients with many different
types of cancer [39, 40]. Results from a phase 3 clinical trial
demonstrated that patients with high mutational burden colo-
rectal cancer who received the anti-PD-1 monoclonal anti-
body pembrolizumab as a first line therapy had a significantly
longer progression-free survival and fewer treatment-related
adverse events than those who received standard chemother-
apy [41]. Further, a growing body of evidence suggests that
high mutational burden tumours are less responsive to con-
ventional chemotherapy [42], which is the routine standard of
care for high mutational burden colorectal cancers. It is hoped
that in the coming years, PD-1 pathway blockades will be-
come the standard first-line treatment for these patients and
expanded to include more patients with high mutational bur-
den tumours.
Epigenetics
Cancer is not only a disease of the genome. In addition to
genomic abnormalities, most cancers display aberrant
epigenomic states, which may arise via several pathways: epi-
genetic priming of cancer-initiating cells [43]; somatic muta-
tions in genes encoding proteins that regulate epigenetic mod-
ifications; and metabolite changes, such as accumulation of
fumarate, which may drive genome-wide methylation chang-
es [44]. These altered epigenetic states may drive oncogenesis,
influence resistance to chemotherapy and resist immune inva-
sion. The epigenome is therefore an attractive therapeutic
target.
At the beginning of the last decade, the DNA methylation
inhibitor azacitidine became a recommended treatment for
haematological malignancies, such as acute myeloid
leukaemia (AML) [45]. More recently there has been a surge
in drug discovery efforts targeting the epigenome—small
molecule inhibitors target gain-of-function mutations, and
loss-of-function mutations can be targeted through synthetic
lethality [46, 47]. Some epigenetic drugs can modulate the
efficacy of immunotherapies, and epigenetic inhibitors have
been shown to overcome drug resistance. Ongoing clinical
trials of epigenetic therapies for many cancers—including a
phase 3 clinical trial investigating the histone deacetylation
inhibitor, entinostat, for breast cancer [48]—will conclude
within the next decade and will likely prompt their clinical
use, especially in combination with other therapies.
Single-Cell RNA-Sequencing
Intratumour heterogeneity is a significant barrier to the effective
treatment of cancer and is regarded as a major driver of resis-
tance to therapy and metastasis [49]. The complex functional
heterogeneity within tumours arises from the genetic heteroge-
neity among malignant cells derived from the genetic variation
and simultaneous Darwinian selection of tumour cells that lead
to their clonal expansion, the plethora of diverse cell types
within the tumour microenvironment and the varied transcrip-
tional responses of tumour cells to factors in the tumour micro-
environment. Recently developed single-cell RNA-sequencing
(scRNA-seq) technologies can finely characterise the
transcriptomic architecture of tumours and their microenviron-
ments. The generation of the Human Cell Atlas, a
knowledgebase containing single-cell transcriptomes from nor-
mal and pathological samples that can act as a reference, has
facilitated the precise cell-type annotation of tumour samples.
Further, scRNA-seq does not require special infrastructure, and
so an increasing number of research studies are employing
scRNA-seq and demonstrating its potential to reveal therapeu-
tic targets within cancer-microenvironment interactions across
a wide range of cancers—from breast cancer [50] to metastatic
lung adenocarcinoma [51] to muscle-invasive urothelial blad-
der cancer [52]. Precision oncology in the future will involve
the functional characterisation of intratumour heterogeneity,
resulting in improved patient outcomes. Within the next de-
cade, it is likely that large-scale scRNA-seq cancer research
studies and clinical trials will be conducted, and we may even
see scRNA-seq emerging into clinical practice.
Personalised Prognosis
The mutational profile of tumours can indicate cancer proper-
ties and disease progression. A Wellcome Sanger Institute
research team has developed an algorithm to predict the out-
comes of patients with AML. The algorithm incorporates the
driver mutations present in the patient’s cancer with other
clinical features, such as the patient’s age at diagnosis, their
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white cell count and the presence of splenomegaly [53•].
Although not yet validated for clinical use, it likely will be
within the next decade, enabling oncologists to deliver
personalised prognoses to AML patients. A similar model
for myeloproliferative neoplasms is currently being devel-
oped, and over the next 10 years, personalised predictors for
many other cancer types will likely be produced and clinically
validated.
Personalised prognoses will inform palliative care deci-
sions and enhance holistic cancer patient care. Often cancer
patients and their families want to know how long they are
expected to live [54]. Clinicians will be better equipped to
answer the common question, “How long do I have left?” A
personalised prediction of life expectancy can empower pa-
tients and their families to make more informed decisions
surrounding end-of-life care and better plan their remaining
time. Additionally, navigating cancer care can be intimidating
for patients as a lot of medical jargon is used. A personalised
prognosis is an easily accessible way of conveying informa-
tion to a patient and their family about their illness.
Personalised prognoses are a noteworthy example of how ge-
nomic medicine advances will enhance all aspects of the
biopsychosocial model of medical practice.
Surveillance
We will soon be able to offer patients personalised cancer sur-
veillance. Non-invasive techniques employed in cancer detec-
tion may also be utilised in the monitoring of patients, with the
potential to transform cancer patient care throughout the thera-
peutic pathway. Serial liquid biopsies will allow us to monitor
patients’ responses to treatments and enable early detection of
emerging therapy-resistant clones within the primary cancer and
metastases. There are promising results from recent studies:
patient-specific mutations in plasma ctDNA have been quanti-
fied to determine tumour burden, monitor response to therapy
and identify relapses earlier in patients with metastatic breast
cancer [55] and colorectal cancer [56]; and microRNAs have
detected micro-metastases in paediatric malignant germ-cell tu-
mours that are undetectable on CT scans [57].
Family Screening
Over the next decade, our understanding of the inherited com-
ponent of cancer risk will continue to expand. Firstly, the
interpretation of germline variants in genes already associated
with increased cancer risk will improve. Bioinformatics re-
search and advances in computational power will facilitate
the development of more advanced data analysis pipelines that
can better functionally annotate and prioritise variants in the
germline genome of cancer patients. Secondly, the wealth of
oncogenomic “big data” available from the NHS Genomic
Medicine Service, and other research consortia such as the
COSMIC database [58], will enable an increasing number of
novel cancer predisposition syndromes to be identified, im-
proving the yield of germline genomic testing. Improved un-
derstanding of heritable cancer risk will enable us to offer
cascade screening to more patients’ families and identify more
at-risk relatives.
Identification of family members with an inherited in-
creased cancer susceptibility will improve following imple-
mentation of recent international recommendations produced
by the European Society of Medical Oncology. These guide-
lines outline a germline-focussed approach to somatic tumour
sequence analysis and have refined the indications for
germline follow-up testing [59]. This will optimise the detec-
tion of clinically useful, true germline variants and improve
the yield of germline follow-up testing.
Furthermore, through the expanding NHS Genomic
Medicine Service, access to genetic counselling will widen,
and more cancer patients and their families will be offered this
invaluable support. By the end of the next decade, an increas-
ing number of cancer patients’ family members will be better
equipped and supported as they navigate their genetic testing
results to make genomic-informed decisions regarding
implementing risk-reducing measures prophylactically.
Challenges
In addition to challenges mentioned above, several other obsta-
cles may hinder the application of genomic medicine advances
to the clinical practice of oncology over the next 10 years.
While the cost of NGS technologies is now relatively low,
the incidence of cancer is both high and increasing [1]. To
provide oncogenomic services for ~367,000 new cancer pa-
tients every year in the UK will be costly [1]. Moreover, the
cost of novel cancer therapies can be high, and so the thresh-
old of improvement in patient outcomes that needs to be dem-
onstrated before their clinical approval may be stringent.
Additionally, the time taken for research studies and clinical
trials to be conducted, their findings published, and the results
translated into clinical practice can be lengthy. The impact of
oncogenomic advances on cancer patient care may therefore
be slower than desired, and many of the advances mentioned
herein may only be emerging in clinical practice towards the
end of the next decade.
Conclusions
Advances in genomic medicine over the next 10 years prom-
ise to revolutionise the care of cancer patients. Critically, we
have never needed personalised medicine in the field of
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oncology more. With the disruption, for over a year, to NHS
cancer services subsequent to the COVID-19 pandemic, there
is an anticipated cancer epidemic [60]. Urgent referrals have
been missed, chemotherapy and surgical treatments have been
halted, and the rate of cancer detection has been much lower
[61]. We face an imminent influx of cancer patients with late-
stage disease and poor prognoses, and there is a pressing need
for the most effective, targeted therapies. Genomic medicine
offers a great deal of hope in these dark times. As we continue
to develop the knowledge and skills to practise precision med-
icine, we hope to deliver for these patients optimal
personalised care. It is my hope that, despite the challenges
we face from the ongoing pandemic, thanks to the promise of
genomic medicine, we will achieve NHS England’s 2028 tar-
get for early diagnosis of 75% of all cancers [27], and that,
over the next 10 years, we will see increased UK cancer sur-
vival rates.
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